Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Ensem Therapeutics
K36 Therapeutics, Inc.
Eli Lilly and Company
Pfizer
Alterome Therapeutics, Inc.
Massachusetts General Hospital
Eli Lilly and Company
Boston Scientific Corporation
VA Office of Research and Development
M.D. Anderson Cancer Center
Stemline Therapeutics, Inc.
Pfizer
Rutgers, The State University of New Jersey
Cancer Research UK
Cancer Research UK
Pathos AI, Inc.
Corcept Therapeutics
Massachusetts General Hospital
Genelux Corporation
University of Pittsburgh
Plus Therapeutics
Turning Point Therapeutics, Inc.
Marengo Therapeutics, Inc.
Cogent Biosciences, Inc.
The First Affiliated Hospital of Guangzhou Medical University
Novartis
Endocyte
Stanford University
UroGen Pharma Ltd.
Karolinska Institutet
VA Greater Los Angeles Healthcare System
Mabwell (Shanghai) Bioscience Co., Ltd.
OncoSil Medical Limited
Taipei Veterans General Hospital, Taiwan
Nanfang Hospital, Southern Medical University
Sociedad Española de Medicina Nuclear e Imagen Molecular
Jiangxi Provincial Cancer Hospital
Concure Oncology-Breast Microseed Inc.